357
Participants
Start Date
November 30, 2025
Primary Completion Date
November 30, 2027
Study Completion Date
November 30, 2028
Single dose of 1800 mg L9LS SC (12mL)
A human monoclonal antibody to protect against Plasmodium falciparum.
Placebo 12 mL SC
Normal saline.
Single dose of 225 mg L9LS SC (1.5mL)
A human monoclonal antibody to protect against Plasmodium falciparum.
Placebo 1.5 mL SC
Normal saline.
Sotuba Malaria Research and Training Center (MRTC), Sotouba
National Institutes of Health (NIH)
NIH
Malaria Research and Training Center (MRTC)
UNKNOWN
Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS)
UNKNOWN
University of Sciences, Techniques, and Technologies of Bamako (USTTB)
UNKNOWN
University of Washington
OTHER
Indiana University School of Medicine, Indiana University
UNKNOWN
National Institute of Allergy and Infectious Diseases (NIAID)
NIH